Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naïve and Concurrently Treated Hypertensive Patients (TRAIL)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00233532

Acronym

TRAIL

Enrollment

2000

Registered

2005-10-06

Start date

2004-03-31

Completion date

Unknown

Last updated

2008-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, Trandolapril

Brief summary

The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

Interventions

DRUGTrandolapril

0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Stage 1 or 2 Hypertension

Exclusion criteria

* Uncontrolled diabetes * Subject has a hypersensitivity to ACE inhibitor

Design outcomes

Primary

Measure	Time frame
Effectiveness of escalating dose regimen of trandolapril in controlling blood pressure	14 weeks

Secondary

Measure	Time frame
Changes in blood pressure, safety.	14 and 26 weeks
BP mmHg incremental and absolute change	14 and 26 weeks
Adverse events	Throughout 26 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026